View PDF Edition - U.S. Pharmacist

More documents

Recommendations

Info

HEALTH SYSTEMS EDITIONMTOR INHIBITORS FOR METASTATIC RENAL CELL CARCINOMAFigure 1. mTOR signaling pathway.mTOR: mammalian target of rapamycin; PI3K:phosphoinositide 3-kinase.multiple kinases, including VEGFR 1–3, PDGFR-alphaand -beta, c-kit, Flt3, colony-stimulating factor receptortype 1, and RET. 4,6Bevacizumab is a monoclonal recombinant humanizedantibody that binds to and neutralizes circulating VEGFligand, which prevents activation of the kinase VEGFR. 2It was FDA-approved in July 2009 in combination withIFN-A for patients with metastatic RCC. Clinical trialsalso demonstrate activity as single-agent therapy. 4Mammalian Target of Rapamycin (mTOR) PathwayThree primary signaling pathways associated with RTKsare currently identified in cancer cells. One of them isthe phosphoinositide 3-kinase (PI3K)/Akt/mTOR proteincascade (FIGURE 1); the other two are the protein kinaseC family and the Ras/mitogen-activated protein kinasecascades. Activation of RTK leads to stepwise activationof PI3K, then Akt, and then mTOR, directly promotingtumor growth. The mutation and overexpression of RTK,as well as growth receptors, are common in RCC. 7Table 1Predictors of Short SurvivalRisk FactorsLDH levelHBCorrected serum calcium levelInterval from original diagnosisto start of systemic treatmentKarnofsky performance scoreNumber of metastatic sitesDescription>1.5 × ULN10 mg/dL
Lilly is committed to meeting the ever-changing needs of our hospital customers.And this commitment drives us to continue working on more innovations for the future.HI59949 1009 PRINTED IN USA ©2009, LILLY USA, LLC. ALL RIGHTS RESERVED.
Page 5 and 6: USE IN SPECIFIC POPULATIONSPregnanc
Page 7 and 8: U.S. PharmacistWhat’s NewsEditori
Page 9 and 10: Q. Which Global Generic Company’s
Page 11 and 12: If key productsare missing from you
Page 13 and 14: 1,500+ WaysWe Meet Your Needs
Page 15 and 16: ✁PATIENT INFORMATIONCombating Fat
Page 17 and 18: Consult Your Pharmacistsleep, wheth
Page 19 and 20: PATIENT TEACHING AIDBipolarDisorder
Page 21 and 22: Our most important ingredient is in
Page 23 and 24: IN THE TREATMENT OF MRSA BACTEREMIA
Page 25 and 26: SCHIZOPHRENIA: A REVIEW OF TREATMEN
Page 28 and 29: SCHIZOPHRENIA: A REVIEW OF TREATMEN
Page 30 and 31: HEALTH SYSTEMS EDITION© JUPITERIMA
Page 32 and 33: FENTANYL TRANSDERMAL SYSTEMBRIEF SU
Page 34 and 35: other opioids, or to subtract the f
Page 36: TRAUMATIC BRAIN INJURYHEALTH SYSTEM
Page 40 and 41: HEALTH SYSTEMS EDITIONNewly Approve
Page 44 and 45: HEALTH SYSTEMS EDITIONMTOR INHIBITO
Page 46 and 47: HEALTH SYSTEMS EDITIONMTOR INHIBITO
Page 48 and 49: HEALTH SYSTEMS EDITIONIn-Service Pr
Page 50 and 51: NUTRITION AND CLINICAL DEPRESSIONHE
Page 52 and 53: NUTRITION AND CLINICAL DEPRESSIONHE
Page 54: NUTRITION AND CLINICAL DEPRESSIONHE
Page 57 and 58: PROGRESSIVE SUPRANUCLEAR PALSYlabil
Page 60 and 61: FDA Fast FactsNew LeukemiaTreatment
Page 62: So Many Options,So Little Differenc
Page 66: WHAT IS THE APPROPRIATE ANTIDEPRESS
Page 75 and 76: WHAT IS THE APPROPRIATE ANTIDEPRESS
Page 77 and 78: OPIOID MAINTENANCE TREATMENTTable 1
Page 79 and 80: KAPIDEX is the first and only PPI w
Page 81 and 82: Nursing Mothers
Page 83 and 84: Table 3Potential Drug Interactions
Page 85 and 86: Providing Affordable andInnovative
Page 87 and 88: GREENSTONELLCWatch Our Product Line
Page 89 and 90: Contemporary Compoundinglevel in le
Page 91 and 92: PHARMACOLOGIC MANAGEMENT OF ALCOHOL
Page 93 and 94:
Zmax: 1 product — indicated for b
Page 95 and 96:
PHARMACOLOGIC MANAGEMENT OF ALCOHOL
Page 97 and 98:
CRIMINALIZATION OF MEDICATION ERROR
Page 99 and 100:
&are excited to launch:www.PharmQD.
Page 101 and 102:
Table 1Early Barriers PreventingUti
Page 103 and 104:
EMERGENCY CONTRACEPTION: AN UPDATEo
Page 105 and 106:
EMERGENCY CONTRACEPTION: AN UPDATEs
Page 107 and 108:
EMERGENCY CONTRACEPTION: AN UPDATE1
Page 109 and 110:
Examination Answer SheetCredits: 2.
Page 111 and 112:
U.S. Pharmacist ClassifiedsCAREER O
Page 113 and 114:
ONGLYZA (saxagliptin) tabletsBrief
show all

View PDF Edition - U.S. Pharmacist

Create successful ePaper yourself

Delete template?

Save as template?